ITGA2 as a potential nanotherapeutic target for glioblastoma
Journal: Boston Children’s Hospital (2019)
Institution: Boston Children’s Hospital
Research Areas: Cancer research
Cell Lines: A172, U87 (A172 - human glioblastoma cell line U87 - human primary glioblastoma cell line)
Summary: Most common and deadly brain cancer type in adults is glioblastoma. Thus, there is an urgent demand to develop an effective targeted therapeutic treatment. P. Gao with colleagues have identified and studied the ITGA2 cell antigen as a potential therapeutic target for glioblastoma. Their research results show that ITGA2 is more expressed in human glioblastoma cells and antigen blocking impedes cell migration. Additionally, authors have developed specified liposomes, which selectively deliver doxorubicin to the cells and inhibit ITGA2. Authors have used HoloMonitor M4 to evaluate the effects of ITGA2 antibody and IgG-conjugated liposome treatment on A172 and U87 cell motility.